Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 702 |
| INN | None |
| Status | Clinical |
| Drug code(s) | HB0034 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | TBD |
| Format, general category | TBD |
| Format details | TBD |
| Isotype (Fc) | TBD |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | IL-36R |
| Indications of clinical studies | Generalized pustular psoriasis, Phase 1 in healthy adults |
| Primary therapeutic area | Immune-mediated / inflammatory disorders |
| Most advanced stage of development (global) | Phase 2/3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | July 01, 2022 |
| Start of Phase 2 | February 29, 2024 |
| Start of Phase 3 | September 15, 2024 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Shanghai Huaota Biopharmaceutical Co. Ltd. |
| Licensee/Partner | None |
| Comments about company or candidate | NCT06477536 Phase 2/3 in Generalized Pustular Psoriasis started in Sep 2024. NCT06231381 Phase 2 in generalized pustular psoriasis started in Feb 2024. NCT05460455 Phase 1 started in Oct 2022; NCT05512598 Phase 1 due to start in Oct 2022. NCT05064345 is A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects |
| Full address of company | 538 Cailun Road, Zhangjiang High Tech Park, Pudong New District, Shanghai Asia China https://www.huaota.com/en/contact.html |
None
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |